In this study, targeted next-generation sequencing using the AmpliSeq for Illumina Cancer HotSpot Panel identified pathogenic mutations in canonical cancer driver genes: tumor protein p53 (<i>TP53</i>) NM_000546.6:c.730G>T (p.Gly244Cys) and platelet-derived growth factor receptor alpha (<i>PDGFRA</i>) NM_006206.6:c.2525A>T (p.Asp842Val) mutations in renal leiomyosarcoma and NRAS proto-oncogene, GTPase (<i>NRAS</i>) NM_002524.5:c.35G>T (p.Gly12Val) mutation in the ovarian tumor. This evidence concerns the gene TP53 and kidney leiomyosarcoma.